BRIEF-Eni Signs Temporary Exclusive Agreement With KKR For Minority Stake In Enilive-March 2024-www.financetom.com

BRIEF-Eni Signs Temporary Exclusive Agreement With KKR For Minority Stake In Enilive

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Eni Signs Temporary Exclusive Agreement With KKR For Minority Stake In Enilive

Jul 22, 2024 11:05 PM

July 23 (Reuters) - Eni SpA ( E ):

* SIGNS TEMPORARY EXCLUSIVE AGREEMENT WITH KKR FOR A

MINORITY

STAKE IN ENILIVE

* AGREEMENT TO SELL 20-25% STAKE IN ENILIVE, ON BASIS OF

TOTAL

VALUATION OF UNIT IN RANGE OF EUR 11.5-12.5 BILLION

Further company coverage:

(Gdansk Newsroom)

Previous page： Raj Subramaniam set to take over as new FedEx CEO Next page： Adani Green gets shareholders' nod for Rs 3850-cr funding by Green Energy Investment

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Raj Subramaniam set to take over as new FedEx CEO

May 3, 2022

In an interaction with CNBC-TV18's Shereen Bhan, FedEx CEO-elect Raj Subramaniam shared his journey from India to the US and how he faced several rejections before getting a job at FedEx in 1991.

Adani Green gets shareholders' nod for Rs 3850-cr funding by Green Energy Investment

May 3, 2022

The deal is a part of the 7.3-billion dirham ($2 billion) investment to be made by the UAE's International Holding Company (IHC) in three Adani Group companies.

SBI Card and Payment Services chief financial officer Nalin Negi quits

May 3, 2022

SBI Cards and Payment Services (SBI Card) on Tuesday said its chief financial officer (CFO) Nalin Negi has resigned from...

COVID vaccine & drug sales help Pfizer sail past forecasts, boost Q1 profit 61%

May 3, 2022

Pfizer's mRNA vaccine, Comirnaty (made in collaboration with BioNTech and yet to be available in India), brought in more than $13 billion in sales, and the treatment Paxlovid added another $1.5 billion as the company's revenue swelled 77 percent.